phx.corporate-ir.net/phoenix.zhtml?c=130148&p=irol-news -
[Cached Version]
Published on: 3/29/2006
Last Visited: 5/24/2007
Mona Haynes Joins Acusphere in Newly Created Position of Vice President, Marketing and SalesACUSPHERE, INC.
...
Mona Haynes Joins Acusphere in Newly Created Position of Vice President, Marketing and Sales
WATERTOWN, Mass., Mar 29, 2006 (BUSINESS WIRE) -- Industry Veteran Selected to Drive AI-700 Commercial Strategy
Acusphere, Inc. (NASDAQ: ACUS) today announced the appointment of Mona Haynes as Vice President, Marketing and Sales.Ms. Haynes joins Acusphere with 25 years of pharmaceutical marketing and sales experience.At Biogen, she had overall marketing responsibility for Avonex(R), which grew from $75 million to $750 million under her leadership.Most recently, at Alkermes, Haynes was responsible for building the marketing function for Vivitrol(TM), a drug that was recently licensed to Cephalon in a transaction valued at about $500 million.
Ms. Haynes is leading an Acusphere marketing team which has over 40 years of combined experience in cardiovascular imaging and includes the ongoing support of Dr. Bill Ramage.
...
Prior to joining Acusphere, Ms. Haynes was responsible for building the marketing function and establishing market development strategies for one of Alkermes' first products, Vivitrol.As part of this achievement, Ms. Haynes developed comprehensive programs to educate and modify the treatment practices in the field of alcohol dependence.Prior to Alkermes, Ms. Haynes served in various senior sales and marketing roles with Biogen and Baxter.At Biogen, she was responsible for developing the marketing strategy that invigorated Avonex sales momentum by utilizing education of patients and physicians to help change the way in which medicine was practiced in the field of Multiple Sclerosis.
"I am very excited by the opportunity to once again influence change in the marketplace by assuring that new products, with new benefits, are understood and available," commented Ms. Haynes."Based on my recent experience in preparing for the launch of Vivitrol, a small and focused team of people working during the period leading up to the filing of an NDA can lay the groundwork for a successful ramp-up in commercialization efforts as the launch approaches.I believe AI-700 will have compelling competitive advantages in a very large and growing market and I am enthusiastic about the opportunity to prepare for and launch this exciting product."
"As we near completion of the clinical phase of our lead product candidate, AI-700, Mona brings valuable commercial market development experience to Acusphere," stated Sherri Oberg, President and CEO at Acusphere.
...
We are very pleased to have Mona join Acusphere to provide marketing expertise, enhance our sales strategy and execution."
35 online sources [ view sources ]
